A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations

Trial status: Authorised • OS in patients treated with osimertinib first followed by dacomitinib and in patients treated with dacomitinib first followed by osimertinib • PFS at the time of study second-line therapy failure (PFS2) in patients treated with front-line osimertinib or dacomitinib; • PFS in patients treated with osimertinib first or dacomitinib first; • Response Rate (RR) with dacomitinib or osimertinib; • RR, PFS and OS with osimertinib followed by dacomitinib or with the opposite sequence in patients with u OS in patients treated with osimertinib first or dacomitinib first

• OS in patients treated with osimertinib first followed by dacomitinib and in patients treated with dacomitinib first followed by osimertinib • PFS at the time of study second-line therapy failure (PFS2) in patients treated with front-line osimertinib or dacomitinib; • PFS in patients treated with osimertinib first or dacomitinib first; • Response Rate (RR) with dacomitinib or osimertinib; • RR, PFS and OS with osimertinib followed by dacomitinib or with the opposite sequence in patients with u

Age group: 65+ years, 18-64 years Gender: Female, Male Target enrollment: 189 participants